Medicare Enrolled
Dr. Lisa Baddi, D.O.
Hematology & Oncology · Chicago, IL
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Baddi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Baddi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Baddi
Dr. Lisa Baddi is a hematology & oncology specialist in Chicago, IL, with 21 years of NPI registration. Based on federal Medicare data, Dr. Baddi performed 60,953 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Baddi received a total of $11,430 from 80 pharmaceutical and/or device companies across 475 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Baddi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 21 years of NPI registration
▲ Top 17% volume in IL
$11,430 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗60,953
Medicare services
Top 17% in IL for hematology & oncology
Not available
Unique patients (not deduplicated)
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Filgrastim injection (Nivestym) for white blood cells An injection of the biosimilar medication filgrastim-aafi (Nivestym) at a dose of 1 microgram. |
15,360 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,550 | $0 | $6 |
| Pembrolizumab injection (Keytruda) | 10,600 | $43 | $137 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
9,740 | $2 | $20 |
| Denosumab injection (Prolia/Xgeva) | 6,480 | $19 | $69 |
| Iron infusion (Monoferric) | 1,500 | $17 | $69 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,280 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 980 | $1 | $114 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
420 | $91 | $824 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
392 | $98 | $231 |
| Anti-nausea injection (ondansetron/Zofran) | 382 | $0 | $3 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
342 | $11 | $93 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
337 | $142 | $325 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
262 | $107 | $686 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
210 | $13 | $105 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
207 | $23 | $152 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
194 | $65 | $168 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
85 | $23 | $156 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
83 | $66 | $157 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
71 | $42 | $115 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
71 | $1 | $7 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
67 | $2 | $19 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
65 | $54 | $334 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
49 | $53 | $304 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
46 | $11 | $73 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
42 | $1 | $17 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
34 | $25 | $249 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
33 | $1 | $9 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
25 | $99 | $232 |
| New patient office visit, complex (60-74 min) | 23 | $172 | $432 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
12 | $145 | $412 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
11 | $109 | $297 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
3.6% high complexity
94.4% medium
2.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,430
Total received (2018-2024)
Avg $1,633/year across 7 years
Top 29% in IL for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
80
Companies
475
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,356
2023
$2,158
2022
$1,516
2021
$1,247
2020
$682
2019
$1,329
2018
$1,143
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$1,107
Novartis Pharmaceuticals Corporation
$398
Gilead Sciences, Inc.
$235
PFIZER INC.
$212
Celgene Corporation
$113
Daiichi Sankyo Inc.
$105
SOBI, INC
$100
ABBVIE INC.
$94
Astellas Pharma US Inc
$81
GlaxoSmithKline, LLC.
$80
E.R. Squibb & Sons, L.L.C.
$77
Incyte Corporation
$74
Pharmacosmos Therapeutics Inc.
$68
Boston Scientific Corporation
$59
Mirati Therapeutics, Inc.
$50
Menarini Silicon Biosystems, Inc.
$48
Amneal Pharmaceuticals LLC
$43
SERVIER PHARMACEUTICALS LLC
$42
SpringWorks Therapeutics, Inc.
$40
PharmaEssentia USA Corporation
$33
ARRAY BIOPHARMA INC
$32
Tempus AI, Inc
$30
Boehringer Ingelheim Pharmaceuticals, Inc.
$29
Blueprint Medicines Corporation
$29
Sumitomo Pharma America, Inc.
$28
Takeda Pharmaceuticals U.S.A., Inc.
$24
Janssen Biotech, Inc.
$24
TAIHO ONCOLOGY, INC.
$23
Genentech USA, Inc.
$21
PUMA BIOTECHNOLOGY, INC.
$20
Kyowa Kirin, Inc.
$17
Biocon Biologics Inc
$16
Iovance Biotherapeutics, Inc.
$6
Top 3 companies account for 51.8% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$1,576
Novartis Pharmaceuticals Corporation
$1,403
Genentech USA, Inc.
$602
PFIZER INC.
$580
Gilead Sciences, Inc.
$577
Celgene Corporation
$407
Merck Sharp & Dohme Corporation
$379
Amgen Inc.
$377
Seagen Inc.
$366
Incyte Corporation
$291
E.R. Squibb & Sons, L.L.C.
$264
Janssen Biotech, Inc.
$256
Merck Sharp & Dohme LLC
$239
Boston Scientific Corporation
$220
Pharmacyclics LLC, An AbbVie Company
$213
Daiichi Sankyo Inc.
$192
GENZYME CORPORATION
$172
Puma Biotechnology, Inc.
$165
Takeda Pharmaceuticals U.S.A., Inc.
$135
ABBVIE INC.
$134
GlaxoSmithKline, LLC.
$134
Bayer HealthCare Pharmaceuticals Inc.
$125
SOBI, INC
$124
Astellas Pharma US Inc
$120
AbbVie, Inc.
$115
Karyopharm Therapeutics Inc.
$106
Inari Medical, Inc.
$104
EMD Serono, Inc.
$99
Boehringer Ingelheim Pharmaceuticals, Inc.
$99
Pharmacosmos Therapeutics Inc.
$83
SERVIER PHARMACEUTICALS LLC
$81
G1 Therapeutics, Inc.
$79
Janssen Pharmaceuticals, Inc
$74
Eisai Inc.
$71
Kite Pharma, Inc.
$68
EISAI INC.
$66
PUMA BIOTECHNOLOGY, INC.
$63
TAIHO ONCOLOGY, INC.
$59
Blueprint Medicines Corporation
$55
Pharmacyclics LLC, an AbbVie Company
$50
Mirati Therapeutics, Inc.
$50
Menarini Silicon Biosystems, Inc.
$48
Deciphera Pharmaceuticals Inc.
$48
Lilly USA, LLC
$45
AVEO Pharmaceuticals, Inc.
$45
Amneal Pharmaceuticals LLC
$43
AMAG Pharmaceuticals, Inc.
$42
Dendreon Pharmaceuticals LLC
$41
SpringWorks Therapeutics, Inc.
$40
JAZZ PHARMACEUTICALS INC.
$40
Verity Pharmaceuticals Inc.
$38
Kyowa Kirin, Inc.
$36
PharmaEssentia USA Corporation
$33
ARRAY BIOPHARMA INC
$32
Biocon Biologics Inc
$32
Tempus AI, Inc
$30
Sumitomo Pharma America, Inc.
$28
NOVARTIS PHARMACEUTICALS CORPORATION
$26
TOLMAR Pharmaceuticals, Inc.
$25
Myriad Genetic Laboratories, Inc.
$25
Jazz Pharmaceuticals Inc.
$25
Verastem, Inc.
$24
Rigel Pharmaceuticals, Inc.
$24
MorphoSys, US Inc.
$24
EUSA Pharma (US) LLC
$22
Sobi, Inc
$19
Regeneron Healthcare Solutions, Inc.
$19
Dova Pharmaceuticals
$18
Midatech Pharma US Inc
$18
Advanced Accelerator Applications
$18
Medtronic USA, Inc.
$17
Secura Bio, Inc.
$17
AbbVie Inc.
$17
Apellis Pharmaceuticals, Inc.
$17
Sun Pharmaceutical Industries Inc.
$16
Clovis Oncology, Inc.
$15
Seattle Genetics, Inc.
$15
Ipsen Biopharmaceuticals, Inc
$15
Helsinn Therapeutics (U.S.), Inc.
$13
Iovance Biotherapeutics, Inc.
$6
Top 3 companies account for 31.3% of all-time payments
Associated products mentioned in payments ›
ABECMA · ADAKVEO · ADCETRIS · ALIMTA · ALOXI · ALUNBRIG · AVASTIN · AYVAKIT · Abraxane · Alecensa · Amtagvi · Avastin · BAVENCIO · BESREMI · BOSULIF · BRAFTOVI · Bavencio · CABLIVI · CALQUENCE · COPIKTRA · COSELA · CT THROMBECTOMY SYSTEM KIT · CYRAMZA · Cellsearch · Copiktra · DARZALEX · DOPTELET · Doptelet · ELIGARD · ELIQUIS · ELREXFIO · ERLEADA · EXALT Model D · Empaveli · Enhertu · Erleada · FERAHEME · FOTIVDA · Fabhalta · Fulphila · GAZYVA · GILOTRIF · Gelclair · Halaven · Hulio · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LENVIMA · LIBTAYO · LONSURF · LORBRENA · LUTATHERA · LYNPARZA · Lenvima · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PIQRAY · PROMACTA · PROVENGE · Padcev · Perjeta · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · RYBREVANT · Revlimid · Rubraca · SANCUSO · SANDOSTATIN · SARCLISA · SCEMBLIX · SUTENT · SYNCHROMED · Somatuline Depot · SpyGlass · Stivarga · Sylvant · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Tavalisse · Tibsovo · Trelstar · Trodelvy · Truqap · VENCLEXTA · VOTRIENT · VYXEOS · Vanflyta · Venclexta · Voranigo · XALKORI · XARELTO · XOSPATA · XPOVIO · XTANDI · Xofigo · Xospata · YONSA · Yescarta · ZEJULA · ZEPZELCA
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
336
County median income
$81,797
Nearest hospital to ZIP centroid (approximate)
AMITA HEALTH RESURRECTION MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Baddi is a mixed practice specialist, with above-average Medicare volume (top 17% in IL), with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Baddi experienced with filgrastim injection (nivestym) for white blood cells?
Based on Medicare claims data, Dr. Baddi performed 15,360 filgrastim injection (nivestym) for white blood cells services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Baddi receive payments from pharmaceutical companies?
Yes. Dr. Baddi received a total of $11,430 from 80 companies across 475 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Baddi's costs compare to other hematology & oncology specialists in Chicago?
Dr. Baddi's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Baddi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Chicago
Browse hematology & oncology specialists in Chicago ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in IL
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in IL
Which IL hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology